Atsushi Hayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsushi Hayashi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Masahide Ohmichi
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7, Daigaku-machi, Takatsuki, Osaka 569-8686, Japan
2 shared publications - Akiko Tanabe
Osaka Medical College
1 shared publication - Atsushi Daimon
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki Osaka, 569-8686, Japan
1 shared publication - Go Nakai
Department of Radiology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka, Japan
1 shared publication - Hidetoshi Satomi
Department of Pathology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki Osaka, 569-8686, Japan
1 shared publication - Hiroko Yuguchi
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki city, Osaka, 569-8686, Japan
1 shared publication
Latest Publications
- Open Access
- 6 October 2015
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 8 (1) , 65
Mitotically active cellular fibroma of the ovary: a case report and literature review
The ovarian cellular fibrous tumor with mitotic figure >4 per 10 high power field without moderate to severe atypia is defined as mitotically active cellular fibroma according to the 2014 World Health Organization classification. As this category is new and rare now, we described here a case of MACF and reviewed the literature. We present a case of mitotically active cellular fibroma of the ovary with 10-year history that was treated with laparoscopic surgery. We reviewed the relevant literature using PubMed search system and analyzed the previous cases. To date, only 5 cases of mitotically active cellular fibroma have been reported. Our patient is the first case of mitotically active cellular fibroma of the ovary treated with laparoscopic surgery. MACF of the ovary is a newly defined category and few cases have been reported, while prognostic factors have also not yet been fully characterized. Long-term clinical follow-up is necessary.
- 6 October 2015
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 8 (1) , 65
Open AccessMitotically active cellular fibroma of the ovary: a case report and literature review
The ovarian cellular fibrous tumor with mitotic figure >4 per 10 high power field without moderate to severe atypia is defined as mitotically active cellular fibroma according to the 2014 World Health Organization classification. As this category is new and rare now, we described here a case of MACF and reviewed the literature. We present a case of mitotically active cellular fibroma of the ovary with 10-year history that was treated with laparoscopic surgery. We reviewed the relevant literature using PubMed search system and analyzed the previous cases. To date, only 5 cases of mitotically active cellular fibroma have been reported. Our patient is the first case of mitotically active cellular fibroma of the ovary treated with laparoscopic surgery. MACF of the ovary is a newly defined category and few cases have been reported, while prognostic factors have also not yet been fully characterized. Long-term clinical follow-up is necessary.
- Open Access
- 1 November 2012
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 5 (1) , 31
Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis
Background: The resistance of endometriotic tissue to progesterone can be explained by alterations in the distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to examine the expressions of PR-A, PR-B, ERα and ERβ in endometrioma and assess whether these expressions are affected by dienogest or leuprolide acetate (LA) treatment. Methods: We enrolled 60 females, including 43 patients with endometriosis (14 who received no medical treatment, 13 who received dienogest and 16 who received LA before undergoing laparoscopic surgery) and 17 patients with leiomyoma. The expression levels of PR and ER isoforms in eutopic and ectopic endometrium were assayed with quantitative real-time PCR, and confirmed with immunohistochemistry. Results: A decreased PR-B/PR-A ratio and an increased ERβ/ERα ratio were demonstrated in ectopic endometrium derived from females with endometriosis compared with the ratios observed in eutopic endometrium obtained from females without endometriosis. Although LA treatment did not affect the PR-B/PR-A and ERβ/ERα ratios, dienogest treatment increased the PR-B/PR-A ratio and decreased the ERβ/ERα ratio in patients with endometriomas. Conclusions: Dienogest may improve progesterone resistance in endometriotic tissue by increasing the relative expressions of PR-B and PR-A, and decreasing the relative expressions of ERβ and ERα.
- 1 November 2012
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 5 (1) , 31
Open AccessDienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis
Background: The resistance of endometriotic tissue to progesterone can be explained by alterations in the distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to examine the expressions of PR-A, PR-B, ERα and ERβ in endometrioma and assess whether these expressions are affected by dienogest or leuprolide acetate (LA) treatment. Methods: We enrolled 60 females, including 43 patients with endometriosis (14 who received no medical treatment, 13 who received dienogest and 16 who received LA before undergoing laparoscopic surgery) and 17 patients with leiomyoma. The expression levels of PR and ER isoforms in eutopic and ectopic endometrium were assayed with quantitative real-time PCR, and confirmed with immunohistochemistry. Results: A decreased PR-B/PR-A ratio and an increased ERβ/ERα ratio were demonstrated in ectopic endometrium derived from females with endometriosis compared with the ratios observed in eutopic endometrium obtained from females without endometriosis. Although LA treatment did not affect the PR-B/PR-A and ERβ/ERα ratios, dienogest treatment increased the PR-B/PR-A ratio and decreased the ERβ/ERα ratio in patients with endometriomas. Conclusions: Dienogest may improve progesterone resistance in endometriotic tissue by increasing the relative expressions of PR-B and PR-A, and decreasing the relative expressions of ERβ and ERα.